

Datasheet

SLC29A1 polyclonal antibody

Catalog Number: PAB2255

Regulatory Status: For research use only (RUO)

Product Description: Rabbit polyclonal antibody raised against synthetic peptide of SLC29A1.

Immunogen: A synthetic peptide (conjugated with KLH) corresponding to internal region of human SLC29A1.

Host: Rabbit

Reactivity: Human, Mouse

Applications: WB-Tr

(See our web site product page for detailed applications information)

Protocols: See our web site at

<http://www.abnova.com/support/protocols.asp> or product page for detailed protocols

Form: Liquid

Purification: Protein A purification

Recommend Usage: Western Blot (1:1000)

The optimal working dilution should be determined by the end user.

Storage Buffer: In PBS (0.09% sodium azide)

Storage Instruction: Store at 4°C. For long term storage store at -20°C.

Aliquot to avoid repeated freezing and thawing.

Entrez GeneID: 2030

Gene Symbol: SLC29A1

Gene Alias: ENT1, MGC1465, MGC3778

Gene Summary: This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative

(as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq]

References:

1. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Br J Cancer. 2014 Sep 23;111(7):1275-84.
2. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Surgery. 2012 Dec 17. pii: S0039-6060(12)00628-9. doi: 10.1016/j.surg.2012.10.010.
3. Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection. Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T. Ann Surg Oncol. 2011 Nov 16.